Patent intelligence · US
US 10300074
Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
Patent details — US 10300074
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2019
- Expiration
- May 23, 2039
- Claims
- 7
- CPC classes
- A61K, A61K31/167, A61K31/18, A61K31/20
Quick answer
US 10300074 (Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy) is held by SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE. Status: granted. Granted May 28, 2019. Expires May 23, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K31/167, A61K31/18, A61K31/20, A61K31/27, A61K31/4045
More from SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 10300074?
US 10300074 (Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy) is held by SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE. Status: granted. Granted May 28, 2019. Expires May 23, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10300074?
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 10300074 expire?
Our index shows an expiration date of May 23, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.